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The aim of this study was to determine the prevalence 
and the types of CTX-M b lactamases produced by Kleb-
siella pneumoniae clinical isolates collected from October 
2006 to January 2007 from both community- and hospital 
– based isolates were included (Figure 1.). 128 ESBL iso-
lates were subjected to further analysis: screening with 
double disc diffusion test and confirmed by ESBL E test15.
Methods and Results
Percentage of ESBL producing isolates was 56 and 44 
from the hospitals and community, respectively. CTX-M was 
detected in 33 (25.8%) isolates. Seventy two strains origi-
nated from hospitals and 56 strains from community. Com-
munity isolates were obtained from outpatients deparment 
and according to medical records did not stay in hospitals 
within previous year. Duplicate isolates were excluded. Only 
single isolates (one isolate per patient) were analyzed.
Introduction
Extended-spectrum b-lactamases (ESBL) producing 
bacteria have been increasingly reported in both hospital 
and community patients. Production of ESBLs is the ma-
jor mechanism of resistance to oxymino-cephalosporins 
and aztreonam in Gram-negative bacteria1,2. Recently a 
new family of ESBLs with predominant activity against 
cefotaxime (CTX-M b-lactamases) has been reported. Over 
80 CTX-M enzymes have been described so far, which can 
be grouped into five main subgroups according to amino 
acid sequence identity (CTX-M-1, CTX-M-2, CTX-M-8, 
CTX-M-9 and CTX-M-25)3. In some countries, CTX-M b-
lactamases are the most prevalent types of ESBLs, for 
instance in Russia4, Greece5, Spain6, Switzerland7, Japan8, 
Taiwan9, China10 and Argentina11. These enzymes have 
been identified in countries near Croatia such is Italy12, 
Hungary13 and Austria14.
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After determination of minimal inhibitory concentra-
tion (MIC), a phenotype consistent with production of 
CTX-M-type b-lactamase was defined by a cefotaxime 
MIC ≥ 8-fold higher than ceftazidime MIC, with the MICs 
of both agents reduced ≥ 8-fold in the presence of 4mg/L 
clavulanic acid. Strains producing CTX-M of group 1 b-
lactamase demonstrated high-level resistance to ceftazi-
dime with uniform susceptibility to carbapenems17,18. El-
evated MICs of ceftazidime in our strains is consistent 
with the production of CTX-M-15 b-lactamase.The rates 
of resistance to non-b-lactam agents, including tetracy-
cline, amikacin, ciprofloxacin and cotrimoxazole for CTX-
M producing K.pneumoniae from hospitals were 85.7%, 
29.4%, 25.3% and 72.1%, from community 87.3%, 25.0%, 
27.1% and 75.2% respectively. There was no resistance 
observed to carbapenems. Based on the conjugation assay 
as describ ed previously19, seven bla genes could be trans-
ferred to transconjugants with the frequency of transfer 
(10–4–10–6) to recipient strain E.coli, suggesting that they 
were plasmid mediated. E. coli A15R- resistant to rifam-
picin was used as recipient in conjugation experiments.
Resistance to chloramphenicol, tetracycline and cotri-
moxazole were cotransferred alongside with CTX resis-
tance from five, two and two isolates, respectively.
Only two isolates cotransfer tetracycline and co-tri-
moxazole resistance to E.coli recipient. In other strains, 
these resistance determinants were not located on trans-
ferable plasmids.
Isolates with a CTX-M phenotype were screened for bla 
CTX-M alleles by multiplex PCR with primers MA-1 (5’-SCS-
ATG-TGC-AGY-ACC-AGT-AA-3’) and MA-2 (5’-CGC-
CRA-TAT-GRT-TGG-TGG-TG-3’). PCR was performed 
under following conditions: 94° for 3 min, the 35 cycles 
consisting of 94°C for 30 s, 55°C for 30 s, and 72°C for 45 
s each, followed by a final extension at 72°C for 5 min. All 
33 isolates were confirmed to produce group 1 CTX-M en-
zyme. More hospital isolates were positive [19 out of 33 
(57.6%)] compared to community [14 out of 33 (42.4%)].
Twenty eight isolates gave a 400 bp PCR product appar-
ently linking an IS26 element with blaCTX-M which previ-
ously reported in the UK18. The blaCTX-M genes from repre-
sentative strains were sequenced using forward (MA-1) 
and reverse (MA-2) primers and primers for group – 1 
CTX-M beta-lactamases in order to amplify the whole 
open – reading frame of blaCTX-M gene.
Sequencing of PCR products of representative strains 
belonging to major clusters revealed the presence of CTX-
M-15-b-lactamases.
Isolation of chromosomal DNA was performed as de-
scribed by Kaufman et al.20. Bacterial genomic DNA was 
compared by using PFGE of Xba I- digested fragments as 
described previously21. The PFGE patterns were compared 
following the criteria of Tenover21 for bacterial strain typ-
ing and analyzed by computer software GelComparII (Ap-
plied Maths, Belgium). An optimization of 0.50% and posi-
tion tolerance of 3.00% was applied during the comparison 
of PFGE fingerprinting patterns. Three of the 33 isolates 
could not be typed using PFGE, due to either difficulties 
CTX-M positive isolates were more prevalent in hospi-
tals (57.6%) than in community (42.4%).
The gender ratio of hospital patients was [29.5%:70.5% 
(female: male)]. The CTX-M positive isolates from hospi-
tals were found mostly in urine samples (47.4 %) but also 
from respiratory tract and wounds. A majority of patients 
were over 60 years old. Sixty patients were older than 60 
years. Twenty one strain (16%) was obtained from respira-
tory tract and twelve (9%) from wound swabs. Urinary 
catheter was not significant risk factor for colonization 
with ESBL producing organism in our study. Previous 
antibiotic therapy was found to be significant risk factor 
for infection or colonization with ESBL producer. Hi 
square test was used to determine the statistical signifi-
cance of the risk factors.
Most patients have been hospitalized in urology units 
or intensive care units. All of CTX-M-15 producers were 
isolated from urine from elderly men and woman (> 60 
years). The gender ratio of community patients was 
[63.3%:36.7% (female: male)]. The CTX-M positive com-
munity isolates originated mostly from urine (93.8%) 
which is in concordance with previous reports16.
Fig. 1. Map of Croatia showing 12 hospitals and 13 Institutes 
of Public Health
CHC Zagreb-1, GH Sv.Duh Zagreb-2, CH Dubrava Zagreb-3, 
IPH Zagreb-4, IPH Varaždin-5, IPH Čakovec-6, GH Koprivnica-7, 
IPH Bjelovar-8, IPH Virovitica-9, GH Pakrac-10,  
GH N. Gradiška-11, GH Požega-12, IPH Sl.Brod-13,  
GH Našice-14, GH Vukovar-15, IPH Osijek-16, IPH Zabok-17, 
GH Zabok-18, IPH Pula-19, IPH Gospić-20, IPH Zadar-21,  
GH Split-22, IPH Split-23, IPH-Dubrovnik-24 and GH Ogulin-25.
CHC-Clinical Hospital Center, GH-General Hospital and 
IPH-Institute of Public Health
Circles indicate participating laboratory, whereas squares 
indicate laboratory in which a detected CTX-M positive strains.
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with lyses of the bacterial cell wall or the digestion of the 
DNA. Typing of the CTX-M producing strains by PFGE 
revealed 14 similarity clusters (I to XIV) three of which, 
I, III and V, were classified as major similarity clusters, 
which have shown specific geographical distribution (Fig-
ure 2). Similarity cluster I harboured 5 of the 33 (15.2%) 
isolates, similarity cluster III harbored 8 of the 33 (24.2%) 
isolates; two isolates produced identical XbaI PFGE pat-
terns, whereas similarity cluster V harboured 3 of the 33 
(9.1%) isolates and they all originated from urine. Cluster 
VII, X and XII harboured two isolates each. Most isolates 
from both community and hospitals belonged to same 
large clusters. The remaining isolates showed unique, un-
related PFGE profiles and were unlikely to be considered 
as outbreaks strains.
Strains 13, 106, 26, 83 are single isolates which showed 
distinct PFGE patterns and were not related to other 
strains.
Although several studies addressed the issue of emer-
gence of CTX-M – producing Klebsiella pneumoniae world-
Fig. 2. Dendrogram of the 33 CTX-M producing Klebsiella pneumoniae.
Dendrogram of the 33 CTX-M producing Klebsiella pneumoniae.The seven columns on the right represent isolate code, centre, inpatient/out-
patient, clinical ward, PFGE type, clinical specimen and date of collection.
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wide, multicenter epidemiological survey has not been 
carried out in Croatia until now. It has only been reported 
that resistance to b-lactam antibiotics is increasing among 
clinical isolates from some hospitals, expressing the need 
for further investigation. In the previous report from our 
country, we have shown presence of group 1 CTX-M pro-
ducing isolates in E.coli 22.
Discussion
The present study is first national survey from twelve 
Croatian hospitals and from the community and offers an 
insight in to the current prevalence and molecular types 
of CTX-M- producing K.pneumoniae in both the hospital 
and community setting. The previous studies have shown 
CTX-M-3 b-lactamase to be the most prevalent in Croa-
tia21. Since blaCTX-M-15 coding region differs from bla CTX-M-3 
by only a single amino acid substitution (Asp240 → Gly) 
it can be hypothesized that bla CTX-M-15 evolved from bla 
CTX-M-3 by point mutation in the coding region of the gene.
A number of risk factors have been identified as linked 
to the acquisition of community-acquired infection involv-
ing CTX-M-positive isolates. These are previous hospital-
ization or antibiotic therapy within the previous 3 month, 
old age (>60 years), male gender and urinary catheteriza-
tion4,23,24. We have found two of above-mentioned risk fac-
tors in our community patients: old age (>60 years) and 
male gender, but did not find prior hospital contact, anti-
biotic therapy nor presence of urinary and vascular cath-
eter in this group of patients.
Our data suggest that CTX-M producers are wide-
spread in at least three regions of Croatia, possibly as a 
consequence of the dissemination of major clones between 
hospitals and community, between regions, and the hori-
zontal transfer of plasmids or mobile elements. The pres-
ence of insertion sequences most likely facilitated the 
spread of bla CTX-M genes and enhanced the expression of 
the genes. The fact that isolates from different hospitals 
were clonally related points out that there was epidemic 
spread of related clones between hospitals in the same 
region. Our data suggest that these clones can spread from 
the community to the hospital and other way around. 
Their incidence may be rising with potential risk of trans-
fer to other bacterial species, like E.coli, especially in com-
munity. This demonstrates the need to monitor both hos-
pitalized and community patients for further emergence 
of transferable resistance to extended-spectrum cephalo-
sporins.
In conclusion, this study highlights the need to estab-
lish an antimicrobial resistance surveillance network for 
K. pneumoniae and to further monitor the trends and new 
resistance mechanisms in the hospitals and the commu-
nity. The factors responsible for the selection and dissem-
ination of the plasmids encoding CTX-M type enzymes 
and clonal dissemination of strains have to be identified, 
controlled and prevented to avoid outbreaks.
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NACIONALNO ISTRAŽIVANJE SOJEVA BAKTERIJE KLEBSIELLA PNEUMONIAE KOJI PROIZVODE 
CTX-M PROŠIRENI-SPEKTAR B-LAKTAMAZA U HRVATSKOJ
S A Ž E T A K
Prošireni spektar beta-laktamaza (ESBL) kojr proizvode bakterije se povišeno pojavljuje kod bolničkih pacijenta I 
pacijenata u zajednici. Proizvodnja ESBL-a je glavni mehanizam otpornosti na oxymino-cefalosporine i aztreoname kod 
gram-negativnih bakterija1,2. Nedavno je zabilježena nova obitelj ESBL-a s dominantnim djelovanjem protiv cefotaksima 
(CTX-M beta-laktamaze). Više od 80 CTX-M enzima je do sada opisano, koji se mogu grupirati u pet glavnih podsku-
pina prema istovjetnosti aminokiselinskog slijeda (CTX-M-1, CTX-M-2, CTX-M-8, CTX-M-9 i CTX-M-25)3. U nekim 
zemljama, CTX-M beta-laktamaze su najzastupljenije vrste ESBL-a, primjerice u Rusiji4, Grčkoj5, Španjolskoj6, 
Švicarskoj7, Japanu8, Tajvanu9, Kini10 i Argentini11. Ovi enzimi su identificirani u zemljama u blizini Hrvatske poput 
Italije12, Madžarske13 i Austrije14. Cilj ovog istraživanja bio je utvrditi učestalost i vrste CTX-M beta laktamaza koje 
proizvode klinički izolati bakterjie Klebsiella pneumoniae prikupljeni od listopada 2006. do siječnja 2007. godine od oba 
u zajednici i bolnica-based izolata su bili uključeni (slika 1.). 128 ESBL izolati bili podvrgnuti daljnjoj analizi: screening 
s dvostrukim disk difuzije testa i potvrđuje ESBL E test15.
